Surgery in Small-Cell Lung Cancer
Small-cell lung cancer (SCLC) is one of the most aggressive tumors, with a rapid growth and early metastases. Approximately 5% of SCLC patients present with early-stage disease (T1,2 N0M0): these patients have a better prognosis, with a 5-year survival up to 50%. Two randomized phase III studies con...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/3/390 |
| _version_ | 1797408926409424896 |
|---|---|
| author | Nicola Martucci Alessandro Morabito Antonello La Rocca Giuseppe De Luca Rossella De Cecio Gerardo Botti Giuseppe Totaro Paolo Muto Carmine Picone Giovanna Esposito Nicola Normanno Carmine La Manna |
| author_facet | Nicola Martucci Alessandro Morabito Antonello La Rocca Giuseppe De Luca Rossella De Cecio Gerardo Botti Giuseppe Totaro Paolo Muto Carmine Picone Giovanna Esposito Nicola Normanno Carmine La Manna |
| author_sort | Nicola Martucci |
| collection | DOAJ |
| description | Small-cell lung cancer (SCLC) is one of the most aggressive tumors, with a rapid growth and early metastases. Approximately 5% of SCLC patients present with early-stage disease (T1,2 N0M0): these patients have a better prognosis, with a 5-year survival up to 50%. Two randomized phase III studies conducted in the 1960s and the 1980s reported negative results with surgery in SCLC patients with early-stage disease and, thereafter, surgery has been largely discouraged. Instead, several subsequent prospective studies have demonstrated the feasibility of a multimodality approach including surgery before or after chemotherapy and followed in most studies by thoracic radiotherapy, with a 5-year survival probability of 36–63% for patients with completely resected stage I SCLC. These results were substantially confirmed by retrospective studies and by large, population-based studies, conducted in the last 40 years, showing the benefit of surgery, particularly lobectomy, in selected patients with early-stage SCLC. On these bases, the International Guidelines recommend a surgical approach in selected stage I SCLC patients, after adequate staging: in these cases, lobectomy with mediastinal lymphadenectomy is considered the standard approach. In all cases, surgery can be offered only as part of a multimodal treatment, which includes chemotherapy with or without radiotherapy and after a proper multidisciplinary evaluation. |
| first_indexed | 2024-03-09T04:06:44Z |
| format | Article |
| id | doaj.art-8f52d164b6de4c64aa7b15fda8de28fd |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T04:06:44Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8f52d164b6de4c64aa7b15fda8de28fd2023-12-03T14:05:58ZengMDPI AGCancers2072-66942021-01-0113339010.3390/cancers13030390Surgery in Small-Cell Lung CancerNicola Martucci0Alessandro Morabito1Antonello La Rocca2Giuseppe De Luca3Rossella De Cecio4Gerardo Botti5Giuseppe Totaro6Paolo Muto7Carmine Picone8Giovanna Esposito9Nicola Normanno10Carmine La Manna11Thoracic Surgery, Istituto Nazionale Tumori, “Fondazione G. Pascale”—IRCCS, 80131 Naples, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyThoracic Surgery, Istituto Nazionale Tumori, “Fondazione G. Pascale”—IRCCS, 80131 Naples, ItalyThoracic Surgery, Istituto Nazionale Tumori, “Fondazione G. Pascale”—IRCCS, 80131 Naples, ItalyPathology, Istituto Nazionale Tumori, “Fondazione G. Pascale”–IRCCS, 80131 Naples, ItalyScientific Directorate, Istituto Nazionale Tumori, “Fondazione G. Pascale”–IRCCS, 80131 Naples, ItalyRadiotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale”–IRCCS, 80131 Naples, ItalyRadiotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale”–IRCCS, 80131 Naples, ItalyRadiology, Istituto Nazionale Tumori, “Fondazione G. Pascale”–IRCCS, 80131 Naples, ItalyThoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyCellular Biology and Biotherapy, Istituto Nazionale Tumori, “Fondazione G. Pascale”—IRCCS, 80131 Naples, ItalyThoracic Surgery, Istituto Nazionale Tumori, “Fondazione G. Pascale”—IRCCS, 80131 Naples, ItalySmall-cell lung cancer (SCLC) is one of the most aggressive tumors, with a rapid growth and early metastases. Approximately 5% of SCLC patients present with early-stage disease (T1,2 N0M0): these patients have a better prognosis, with a 5-year survival up to 50%. Two randomized phase III studies conducted in the 1960s and the 1980s reported negative results with surgery in SCLC patients with early-stage disease and, thereafter, surgery has been largely discouraged. Instead, several subsequent prospective studies have demonstrated the feasibility of a multimodality approach including surgery before or after chemotherapy and followed in most studies by thoracic radiotherapy, with a 5-year survival probability of 36–63% for patients with completely resected stage I SCLC. These results were substantially confirmed by retrospective studies and by large, population-based studies, conducted in the last 40 years, showing the benefit of surgery, particularly lobectomy, in selected patients with early-stage SCLC. On these bases, the International Guidelines recommend a surgical approach in selected stage I SCLC patients, after adequate staging: in these cases, lobectomy with mediastinal lymphadenectomy is considered the standard approach. In all cases, surgery can be offered only as part of a multimodal treatment, which includes chemotherapy with or without radiotherapy and after a proper multidisciplinary evaluation.https://www.mdpi.com/2072-6694/13/3/390small-cell lung cancerlobectomypneumonectomyradiotherapychemotherapymultimodal treatment |
| spellingShingle | Nicola Martucci Alessandro Morabito Antonello La Rocca Giuseppe De Luca Rossella De Cecio Gerardo Botti Giuseppe Totaro Paolo Muto Carmine Picone Giovanna Esposito Nicola Normanno Carmine La Manna Surgery in Small-Cell Lung Cancer Cancers small-cell lung cancer lobectomy pneumonectomy radiotherapy chemotherapy multimodal treatment |
| title | Surgery in Small-Cell Lung Cancer |
| title_full | Surgery in Small-Cell Lung Cancer |
| title_fullStr | Surgery in Small-Cell Lung Cancer |
| title_full_unstemmed | Surgery in Small-Cell Lung Cancer |
| title_short | Surgery in Small-Cell Lung Cancer |
| title_sort | surgery in small cell lung cancer |
| topic | small-cell lung cancer lobectomy pneumonectomy radiotherapy chemotherapy multimodal treatment |
| url | https://www.mdpi.com/2072-6694/13/3/390 |
| work_keys_str_mv | AT nicolamartucci surgeryinsmallcelllungcancer AT alessandromorabito surgeryinsmallcelllungcancer AT antonellolarocca surgeryinsmallcelllungcancer AT giuseppedeluca surgeryinsmallcelllungcancer AT rosselladececio surgeryinsmallcelllungcancer AT gerardobotti surgeryinsmallcelllungcancer AT giuseppetotaro surgeryinsmallcelllungcancer AT paolomuto surgeryinsmallcelllungcancer AT carminepicone surgeryinsmallcelllungcancer AT giovannaesposito surgeryinsmallcelllungcancer AT nicolanormanno surgeryinsmallcelllungcancer AT carminelamanna surgeryinsmallcelllungcancer |